At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed primary adenocarcinoma of the breast, Stage I-III
- ✓Surgery (lumpectomy or mastectomy) within past 12 weeks OR completed chemotherapy within past 8 weeks
- ✓Currently receiving or planning to receive standard adjuvant systemic therapy (chemotherapy, hormonal therapy, or combined)
- ✓No evidence of metastatic disease (including negative bone scan/imaging if skeletal pain present)
- ✕Low-risk patients for whom adjuvant systemic therapy will not be prescribed
- ✕Patients receiving biologic agents only or local radiotherapy only (without chemotherapy and/or hormone therapy)
- ✕History of esophageal stricture or motility disorders
- ✕Other malignancy within past 5 years (except adequately treated skin cancer, cervical CIS, or Stage I-II cancer in complete remission)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
In Brief
A Phase 3 clinical trial evaluating clodronate disodium, ibandronate sodium, and 1 other intervention for Breast Cancer. Completed, enrolled 6,097 participants.
Detailed Summary
RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Study Details
Timeline
Interventions
Given orally
Given orally
Given IV